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ESCITALOPRAM (LEXAPRO) is the most recent selective sero-tonin reuptake inhibitor (SSRI) approved by the United
States Food and Drug Administration (FDA) in 2002 for treat-
ment of adults with major depressive disorder, social anx-
iety disorder, and generalized anxiety disorder. To date, it
has not been approved for use in children or adolescents, as
data regarding its safety and efficacy in youths is insuffi-
cient. However, it is often prescribed off label in this popu-
lation for similar indications.
This report describes a 17-year-old girl with a history of
major depressive disorder and congenital deformity of the
upper limbs who developed allergic interstitial nephritis and
acute renal failure during a course of treatment with esci-
talopram.
Chief Complaint and Presenting Problem
R. was a 17-year-old Caucasian girl and junior in high
school who lived with her parents and 13-year-old sister. She
was transferred from another hospital with acute renal fail-
ure possibly secondary to escitalopram use, which she had
taken for treatment of major depressive disorder. She was
subsequently referred to the inpatient consultation team for
medication evaluation and management.
History of Present Illness
R. had a history of mood and behavioral problems with
onset over a year ago when she was 16 years of age. She was
described as often irritable, snapping, talking back, and op-
positional. She experienced a period of time when her peers
teased her about her congenital deformity. She began to have
difficulty maintaining her grades in school. She had crying
spells, negative thoughts about herself, and feelings of
worthlessness. She reported that she did not feel like she
wanted to live any more. On one occasion, she scratched her
wrists with a pin, and on another occasion, with a knife; these
self-injurious behaviors were reportedly suggested to her by
a friend. She reported feeling better after scratching and cut-
ting herself and denied any intention to die.
Past Psychiatric History
R. started psychotherapy with a psychologist for depres-
sion when she was approximately 16 years old. Escitalopram
10 mg was subsequently initiated by her primary care physi-
cian. She continued on this dose for 6 months without any
adverse effects. The dose was then increased to 20 mg when
it became apparent that her depression was not well con-
trolled. After four months at 20 mg, there was a significant
improvement as a result of therapy and medication, so her
mother stopped the medication for a week. The patient was
also discharged from the therapist’s care due to her symp-
tomatic improvement.
When R. returned for follow-up to the primary care physi-
cian, it was recommended that she continue taking medica-
tion, as it was felt that the remission of her depressive symp-
toms was too recent to be likely to be sustained. The
recommendation was to continue the escitalopram for the
next year, her junior year in high school, and then discon-
tinue it.
There was no previous history of psychiatric treatment or
treatment with any other psychotropic medications.
Developmental History
R. was the product of a full term, uncomplicated preg-
nancy and vaginal delivery. She was born with a congenital
defect of bilateral hemimelia of her upper limbs. Her devel-
opmental milestones were on target except for walking,
which she did not achieve until 18 months, as she was un-
able to use her hands for support.
Educational History
R. was an eleventh grade student at a public high school.
Her grades averaged Cs and Ds. She liked math but not sci-
ence. She had an Individualized Educational Plan for her dis-
ability which provides accommodations.
Social History
R. lived with her biological parents and 13-year-old sister.
She reported that she felt her parents were harsh with her,
especially her father. She denied any abuse or trauma. She
had a few close friends at school. She had experienced teas-
ing by her peers about her disability. She had a boyfriend
who her mother approved.
Family History
A.’s mother reported that she had taken alprazolam for
anxiety in the past. There was no family history of renal dis-
ease or other psychiatric disorders.
Medical History
R. had a past history of polyuria, which was never inves-
tigated, and thus there was no known diagnosis of renal
problems. She also had used an unknown dose of ibuprofen
3-4 days per month for menstrual cramps.
Mental Status Examination
R. was wearing a bright pink dressing gown over her
clothes, which covered her arms. She was fairly pleasant, and
co-operative. Rapport was established and eye contact was
maintained. She was able to use a pincer-like grip and was
able to perform tasks such as unscrewing a bottle cap.
Her psychomotor activity level was appropriate to the sit-
uation. Her speech and language was notable for normal
pressure and volume. Her affect was appropriate to the sit-
uation and revealed a fairly good range. Her mood was eu-
thymic. Her thought process and form were coherent and
goal-directed.
R. denied any current negative thoughts about herself or
the future. She reported that she was satisfied with the care
she had received and stated that this experience made her
more appreciative of everything she has, including her fam-
ily. She described feeling hopeful and wanting to live her
life, so that she could become a psychologist and have a baby.
She denied any current suicidal ideation, intent, or plan. She
did report that she believed her parents were unreasonable
at times. She stated that therapy has helped her put things
in perspective and allowed her to better appreciate them.
R. was alert and oriented with intact attention/concen-
tration and recent and remote memory. Her fund of knowl-
edge was average, and her insight and judgment were fair.
Clinical Course
Two to three weeks after restarting escitalopram, R. began
to have nausea and vomiting followed by abdominal pain
and diarrhea. Over the next 3 weeks, she was treated symp-
tomatically with metoclopramide, which provided tempo-
rary relief, but the nausea, vomiting, and pain continued to
recur. She also had one episode of dark black stools. She de-
nied both having overdosed on the medication and taking
extra pills. During that time, she was also given a prescrip-
tion for alprazolam 0.5 mg twice daily as needed, for anx-
iety relating to her medical problems, which she took for a
total of 6 times over 1 month.
She was subsequently taken to a local hospital where she
was diagnosed with acute renal failure. Her creatinine at that
time was 4.9 mg/dl (normal range: 0.5–1 mg/dL) and her
glomerular filtration rate was 12 (normal range: 60–80
mg/mL/m2). No specific cause for renal failure was identi-
fied.
A renal ultrasound was performed, which demonstrated
normal kidney appearance, normal flow on color Dopplers,
and no collecting system dilatation. Renal biopsy was in-
conclusive, as the sample was inadequate. R. was also found
to be anemic, but no gastrointestinal source for bleeding was
identified.
Escitalopram was discontinued 4 days after the diagnosis
of renal failure was made. The workup revealed moderate
eosinophiluria and eosinophilia, which was suggestive of
drug-induced allergic interstitial nephritis. At time of dis-
charge one week later, her creatinine had reduced to 2.1
mg/dL, and her symptoms had improved.
Brief Formulation
In summary, R. is a 17-year-old Caucasian girl with a
history of major depressive disorder treated with a 10
month course of escitalopram. She presented for admission
with nausea, vomiting, and abdominal pain consistent
with acute renal failure, possibly due to the escitalopram.
Her renal function improved with discontinuation of the
medication.
From the biological/medical perspective, given her past
history, escitalopram might have worsened a previously ex-
isting, undiagnosed renal disorder, either by itself or in com-
bination with the nonsteroidal antiinflammatory agent.
There is evidence that R.’s depression responded well to
treatment with escitalopram and psychotherapy without any
adverse events prior to the onset of acute renal failure. In ad-
dition, R. may have had a diathesis for affective illness, given
the family history of anxiety on the maternal pedigree. Fur-
thermore, R.’s physical disability appeared to be an under-
lying issue for which she felt vulnerable, and had not yet
been able to successfully deal with this with her peers, which
may have rendered her more vulnerable to low self esteem
and negative self image. From a psychological perspective,
R. appeared to be dealing with typical adolescent develop-
mental issues with her parents, but did experience them
overall as supportive and involved. Socially, on the positive
side, she had been able to achieve a relationship with a
boyfriend, despite her difficulties, and she had plans for the
future.
Multiaxial Diagnoses
Axis I: Major depressive disorder, single, in full remission
Axis II: Deferred; rule out borderline features
Axis III: Acute allergic interstitial nephritis
Acute renal failure, possibly secondary to escitalopram
Hemimelia.
Axis IV: Interpersonal problems with peers.




Although there is no conclusive evidence for the causative
role of escitalopram in renal failure in this patient, this case
brings up several important issues in clinical pediatric psy-
chopharmacology practice, including choice of medication,
and the role of previous medical history.
To date, there is only one controlled trial of escitalopram
in the treatment of major depressive disorder in children and
adolescents (Wagner et al. 2006). There are no formally es-
tablished guidelines for dosing or duration for escitalopram
in youth. Escitalopram is recommended as a second-line
agent as monotherapy for treatment-resistant depression in
the Texas Childhood Medication Algorithm, due to the
paucity of controlled trials in adolescents. SSRIs for which
there is an evidence base for treatment of major depression
in youth include fluoxetine, citalopram and sertraline
(Hughes et al. 2007, Emslie et al. 2002, Wagner et al. 2004,
Wagner et al. 2003, March et al. 2004).
In the absence of level A (randomized controlled trial)
data, many psychiatrists prescribe antidepressants for chil-
dren and adolescents that have been beneficial to their first
degree relatives; however, this appears does appear to have
been the case with R. Thus, one could question the use of
this agent as a first-line treatment when the extant evidence
base is stronger for several of the older agents.
With regard to pharmacokinetics, the difference in the
plasma concentrations of a single dose of escitalopram be-
tween healthy adolescents and adults is not significant (Rao
2007). It is primarily metabolized in the liver by enzymes
CYP3A4 and 2C19 with 8% of drug excreted unchanged in
urine. The most common adverse effects reported in adults
with escitalopram are nausea, insomnia, ejaculation disor-
der, diarrhea, fatigue, dry mouth, and sweating.
The single controlled trial of escitalopram in youth was an
8-week double-blind study in adolescents with depression;
results revealed a high incidence of headache and abdomi-
nal pain(Wagner et al. 2006). In a 10-week open label trial in
children with Pervasive Developmental Disorder, the most
common side-effects reported were irritability and hyperac-
tivity (Owley et al. 2005). In a case series of 5 adolescents
treated with escitalopram for major depression, there were
no reports of significant adverse events (Schaller and Rawl-
ings 2005.
Most depressive illness in youth is usually of long dura-
tion, lasting months to years. However, there is little evi-
dence base for long-term treatment greater than 8–12 weeks
with any of the SSRIs; there is a report of long-term use of
citalopram up to one year (Thomsen et al. 2001.
Taken together, we cannot be sure that the drug, dose or
duration of treatment with escitalopram was causative of her
acute renal failure; both her past history of polyuria and
chronic use of ibuprofen could have rendered her vulnera-
ble to development of renal problems, independent of esci-
talopram.
Drugs associated with allergic interstitial nephritis include
antibiotics, anticonvulsants, and diuretics. Though rare, non-
steroidal anti-inflammatory drugs (NSAIDs have also been
associated with allergic nephritis and renal failure (Agarwal
et al. 2003).
In practice, patients often use NSAIDs without the clini-
cian’s knowledge and do not volunteer the information un-
less specifically asked. NSAIDs are not benign, and, in com-
bination with SSRIs, may increase the risk of bleeding. In-
terestingly, R. did present with anemia, although no source
of bleeding or overt cause was determined. A more complete
workup would be indicated.
Our conclusion is that escitalopram should be used with
caution in children and adolescents. First-line treatment
with one of the SSRIs with an established evidence base of
safety and tolerability is indicated, such as fluoxetine, ser-
traline, and citalopram. The clinician should be vigilant to
the possibility of new onset of any medical complaints dur-
ing treatment, particularly until further data is compiled
regarding its safety and efficacy in children and adoles-
cents.
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